Analyzing Mateon Therapeutics (OTCMKTS:MATN) & Rapport Therapeutics (NASDAQ:RAPP)

Mateon Therapeutics (OTCMKTS:MATN) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Profitability

This table compares Mateon Therapeutics and Rapport Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
Rapport Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Mateon Therapeutics and Rapport Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mateon Therapeutics	0	0	0	0	0.00
Rapport Therapeutics	0	0	3	0	3.00

Rapport Therapeutics has a consensus price target of $35.00, suggesting a potential upside of 56.32%. Given Rapport Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Rapport Therapeutics is more favorable than Mateon Therapeutics.

Earnings & Valuation

This table compares Mateon Therapeutics and Rapport Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	N/A	N/A
Rapport Therapeutics	N/A	N/A	-$34.79 million	N/A	N/A

Institutional and Insider Ownership

0.1% of Mateon Therapeutics shares are owned by institutional investors. 39.2% of Mateon Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rapport Therapeutics beats Mateon Therapeutics on 5 of the 8 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.